Gabapentin for Essential Tremor
Gabapentin is a second-line agent for essential tremor that is probably effective as monotherapy but should not be used as adjunct therapy, with dosing starting at 300 mg three times daily and titrating up to 1800-3600 mg/day over several weeks.
Evidence Quality and Positioning
The most recent high-quality evidence from 2025 meta-analysis 1 found no significant advantage of gabapentin over placebo in between-group comparisons, though within-group analyses showed gabapentin (but not pregabalin) significantly reduced tremor severity from baseline. This conflicts with older American Academy of Neurology guidelines from 2011 2 that classified gabapentin monotherapy as "probably effective" (Level B evidence).
The 2020 neurosurgery guideline 3 explicitly states that second-line medical therapies including gabapentin are not as effective as first-line therapies (propranolol and primidone).
Treatment Algorithm
When to Consider Gabapentin
Use gabapentin only when:
- First-line agents (propranolol, primidone) have failed due to lack of efficacy, intolerable side effects, or contraindications
- Patient cannot tolerate beta-blockers (e.g., COPD, asthma, heart block)
- Patient has failed primidone due to sedation or ataxia
- Do NOT use as add-on therapy to existing tremor medications - evidence shows it is ineffective as adjunct therapy 2
Dosing Protocol
Starting dose: 300 mg at bedtime OR 100-300 mg three times daily 4
Titration schedule:
- Increase by 100-300 mg every 1-7 days as tolerated 4
- Target therapeutic range: 1800-3600 mg/day in three divided doses
- Maximum interval between doses: 12 hours
Adequate trial duration: 3-8 weeks for titration plus 2 weeks at maximum tolerated dose 5 - meaning an adequate trial requires 2 months or more 5
Renal Dosing Adjustments
Gabapentin requires dose reduction in renal impairment 4:
- CrCl ≥60 mL/min: 900-3600 mg/day (300-1200 mg TID)
- CrCl 30-59 mL/min: 400-1400 mg/day (200-700 mg BID)
- CrCl 15-29 mL/min: 200-700 mg/day (200-700 mg once daily)
- CrCl <15 mL/min: 100-300 mg once daily
- Hemodialysis: Maintenance dose based on CrCl plus supplemental 125-350 mg post-dialysis
Monitoring and Side Effects
Common adverse effects:
- Dose-dependent dizziness and sedation (reduce by slow titration) 5
- Somnolence
- Ataxia
Monitoring parameters:
- Tremor severity using clinical rating scales
- Functional disability in activities of daily living
- Renal function (adjust dose accordingly)
- Elderly patients require particular attention to dose selection based on creatinine clearance 4
Critical Caveats
Nonlinear pharmacokinetics: Gabapentin has saturable absorption, requiring careful dose titration 5. This is why pregabalin (with linear kinetics) may be preferred by some clinicians, though evidence for pregabalin in ET is even weaker.
Mixed evidence quality: The 2025 meta-analysis 1 contradicts older positive trials 6, 7. The Italian Movement Disorders Association (2013) 8 recommends gabapentin only as second-line therapy with "low" quality evidence.
Discontinuation: Taper gradually over minimum 1 week when stopping 4 to avoid withdrawal symptoms.
FDA indication: Gabapentin is NOT FDA-approved for essential tremor 4 - approved only for postherpetic neuralgia and partial seizures. This is off-label use.
Realistic Clinical Expectations
Based on the 2000 controlled trial 6, when gabapentin works, expect:
- Improvement in patient global assessments
- Reduction in observed tremor scores
- Better water pouring performance
- Improved activities of daily living scores
- No improvement in accelerometry or investigator assessments in some studies
The 1999 comparative trial 7 showed gabapentin and propranolol had comparable efficacy at day 15, but propranolol remains first-line due to more consistent evidence.
Bottom Line
Gabapentin is a reasonable third-line option after propranolol and primidone failure, used as monotherapy at 1800-3600 mg/day divided three times daily, with slow titration over 2+ months to assess efficacy. The most recent evidence suggests limited benefit over placebo, so set realistic expectations with patients and consider surgical options (DBS, thalamotomy) if multiple medications fail 3, 9.